The US Office of Inspector General (OIG) issued a report showing only 2% of hospitals are considering building their own 503B operation, given equipment, facility design, and “huge leap in cost and talent” are major limitations…

“To provide FDA with insights to improve its oversight of compounders and enhance patient safety, OIG determined the extent to which hospitals purchase non-patient-specific compounded drugs from outsourcing facilities…”

Read more: Most Hospitals Obtain Compounded Drugs From Outsourcing Facilities, Which Must Meet FDA Quality Standards

Full report

Evaluating a new 503B partner, or just auditing your current partner?

Download this valuable checklist to help you assess their quality and compliance.